Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials

湿疹面积及严重程度指数 医学 特应性皮炎 随机对照试验 临床终点 不利影响 非甾体 内科学 皮肤病科
作者
Atsuyuki Igarashi,Gaku Tsuji,Shuichi Fukasawa,Ryusei Murata,Satoshi Yamane
出处
期刊:Journal of Dermatology [Wiley]
卷期号:51 (11): 1404-1413 被引量:22
标识
DOI:10.1111/1346-8138.17451
摘要

Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream 1% in Japanese patients aged ≥12 years with atopic dermatitis (AD) in two phase 3 trials, ZBB4-1 and ZBB4-2. ZBB4-1 (N = 216) consisted of an 8-week, double-blind, vehicle-controlled treatment period (period 1) and a 16-week extension treatment period (period 2). Patients were randomized 2:1 to tapinarof or vehicle in period 1; subsequently, all patients who enrolled in period 2 received tapinarof. ZBB4-2 (N = 291) was a 52-week, open-label, uncontrolled trial in which all patients received tapinarof. In period 1 of ZBB4-1, the proportion of patients who achieved an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at week 8 (IGA treatment success, the primary end point) was 20.24% in the tapinarof group and 2.24% in the vehicle group (p = 0.0007). The proportion of patients with ≥75% improvement from baseline in Eczema Area and Severity Index (EASI) score at week 8 (EASI-75 response, the key secondary end point) was 40.3% in the tapinarof group and 4.3% in the vehicle group (p < 0.0001). In ZBB4-2, IGA treatment success rate was 28.1% at week 16, 32.3% at week 24, and 41.3% at week 52, and EASI-75 response rate was 53.3% at week 16, 63.7% at week 24, and 76.6% at week 52, indicating that efficacy responses improved over time and were maintained over 52 weeks. Across the two trials, most adverse events (AEs) were mild or moderate; common AEs included folliculitis, acne, and headache. In summary, tapinarof cream 1% was effective and generally safe for up to 52 weeks of treatment in Japanese patients with AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被LUO采纳,获得10
刚刚
搜集达人的应助被哈哈哈哈采纳,获得10
1秒前
传奇3的应助被zzy采纳,获得10
1秒前
斯文败类的应助被Mrzhao采纳,获得10
2秒前
Momoka发布了新的文献求助10
2秒前
梦寐寤寐发布了新的文献求助10
3秒前
3秒前
科研通AI6.4的应助被科研汪采纳,获得10
4秒前
4秒前
JJ发布了新的文献求助10
5秒前
6秒前
6秒前
无极微光的应助被研友_89N27L采纳,获得20
6秒前
7秒前
羊羊羊完成签到 ,获得积分10
7秒前
yhy完成签到,获得积分10
7秒前
7秒前
小九九发布了新的文献求助10
7秒前
Akim的应助被Jeccy采纳,获得10
7秒前
丘比特的应助被juju采纳,获得30
8秒前
星辰大海的应助被淡淡冷荷采纳,获得10
9秒前
10秒前
华仔的应助被WYL采纳,获得10
10秒前
笑逆发布了新的文献求助10
10秒前
SciGPT的应助被蒋畅采纳,获得10
11秒前
wjh发布了新的文献求助10
11秒前
GIN的应助被麻辣王子采纳,获得20
12秒前
12秒前
13秒前
13秒前
14秒前
谦让的斓发布了新的文献求助10
14秒前
十六完成签到 ,获得积分10
14秒前
15秒前
乔达摩完成签到 ,获得积分0
15秒前
11完成签到,获得积分10
16秒前
超级无敌霹雳锦鲤完成签到,获得积分10
16秒前
乐观阑悦完成签到 ,获得积分10
17秒前
LUO发布了新的文献求助10
17秒前
12发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128